Clinical Pharmacology of Inodilators

Dei, Livio; Metra, M.; Visioli, O

doi:10.1097/00005344-198906148-00006

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a systemic level, low-dosage ibopamine does not affect the arterial pressure during either the short or the long term [33,35,36]. In our study no significant pressure differences were found between the two groups during the observation period.…”

Section: Discussionmentioning

confidence: 46%

“…At the doses used in the study (low dosage 100 mg/ day), the action of ibopamine on the kidney occurs through stimulation of the dopaminergic receptors DAI and DA2 [33][34][35], This stimulation is followed by an increase in renal plasma flow, with dilation of both the afferent and the efferent arterioles, most likely without an increase in intraglomerular pressure [38][39][40][41][42].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Low-Dosage Ibopamine Treatment in Progressive Renal Failure: A Long-Term Multicentre Trial

Stefoni

Mosconi²,

Manna³

et al. 1996

Am J Nephrol

View full text Add to dashboard Cite

A multicentre trial (11 nephrology centres) was carried out to test the effects of ibopamine, an orally active dopamine-like drug, on the progression of chronic renal failure. For a 2-year period 189 chronic renal failure patients (serum creatinine level 1.5-4.0 mg/dl) were observed. They were homogeneous for basic nephropathy, degree of residual renal function, blood pressure, and proteinuria. the patients were randomly divided into two groups: 96 took ibopamine at a dosage of 100 mg/day (group A) and 93 served as controls (group B). All were on a low-protein diet (mean 0.8 g/kg body weight). By the end of the observation period, the rate of decrease of the renal function indexes in time proved significantly slower (1.8 times) in group A than in group B. The survival curves for renal function (pre-established end points were creatinine level increases equal to or > 20% and equal to or > 40% of the basal values) proved significantly better (p < 0.02 and p < 0.002 respectively) in group A than in group B. The mean plasma creatinine values rose by 17% in group A and by 36% in group B. The creatinine clearance decreased by 5% in treated patients and by 14% in the controls. Statistical analysis ruled out any possible centre effect. The trial suggests that low-dosage ibopamine administration may be used as a valid and safe pharmacological adjunct for retarding the progression of renal failure in patients with mild or moderate chronic renal impairment.

show abstract

Section: Discussionmentioning

confidence: 46%

Section: Discussionmentioning

confidence: 99%

Low-Dosage Ibopamine Treatment in Progressive Renal Failure: A Long-Term Multicentre Trial

Stefoni

Mosconi²,

Manna³

et al. 1996

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…Ibopamine is an orally active dopamine agonist which has been shown to activate dopaminergic receptors DA1 and DA2 at daily doses of 100-200 mg, β-adrenergic receptors at 300-400 mg, and α-adrenergic receptors at greater than 400 mg. 6,7 Its pharmacological effect is maintained over prolonged periods. 8,9 Both in normal subjects and in patients with mild renal impairment, ibopamine administration has produced an increase in renal plasma flow, an increase in 99m Tc-DTPA clearance, a reduction in filtration fraction and an increase in sodium excretion and diuresis.…”

Section: Ibopaminementioning

confidence: 99%

Other agents

Johnson¹

2006

Nephrology

View full text Add to dashboard Cite

Suggestions based on level III and IV sources)• There is limited evidence to suggest that the progression of certain forms of renal disease is retarded by nonsteroidal anti-inflammatory drugs (NSAIDs), (Level III evidence; several retrospective and prospective cohort studies; mostly surrogate outcome measures; consistent weak effect) and by combined ketaconazole and prednisone (Level II-III evidence; single small cross-over study; clinically relevant outcome; weak effect). However, these benefits are outweighed by the serious side-effects of these medications and their use cannot be currently recommended. BACKGROUND

show abstract